انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
Paradigm Shifting Updates in IgAN: Expert Faculty Discussions of Recent Breakthroughs
Manage episode 438997950 series 3242427
In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients’ kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies.
Topics include:
- Supportive care as the foundation of IgAN management
- Place in therapy for new and emerging agents
- Targeted-release formulation of budesonide
- Endothelin receptor antagonists (eg, sparsentan)
- Factor B inhibitors (eg, iptacopan)
- The role of clinical trial involvement
Learn more about IgA nephropathy with educational activities and resources here:
31 حلقات
Manage episode 438997950 series 3242427
In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients’ kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies.
Topics include:
- Supportive care as the foundation of IgAN management
- Place in therapy for new and emerging agents
- Targeted-release formulation of budesonide
- Endothelin receptor antagonists (eg, sparsentan)
- Factor B inhibitors (eg, iptacopan)
- The role of clinical trial involvement
Learn more about IgA nephropathy with educational activities and resources here:
31 حلقات
كل الحلقات
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.